Stockscreener 앱 받기
2.94
0.00%
0.00
시간 외 거래:
2.96
0.02
+0.68%
전일 마감가:
$2.94
열려 있는:
$2.96
하루 거래량:
2.89M
Relative Volume:
0.82
시가총액:
$631.11M
수익:
$12.87M
순이익/손실:
$-114.34M
주가수익비율:
-3.4004
EPS:
-0.8646
순현금흐름:
$-79.23M
1주 성능:
+8.09%
1개월 성능:
+17.13%
6개월 성능:
+80.37%
1년 성능:
+28.38%
1일 변동 폭
$2.85
$2.99
1주일 범위
$2.685
$3.12
52주 변동 폭
$1.05
$3.31
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
TSHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
2.94 | 802.02M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | BofA Securities | Buy |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
Wells Fargo Raises Taysha Gene Therapies Target Price to $8.00 Amid 'Overweight' Rating - AInvest
BofA Securities Affirms ‘Buy’ Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects - MSN
Institutional Investors Are Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Biggest Bettors and Were Rewarded After Last Week's US$199m Market Cap Gain - 富途牛牛
Taysha Gene Therapies Inc. Consolidation Zone May Signal Accumulation2025 Fundamental Recap & Real-Time Volume Analysis Alerts - metal.it
Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome treatment boosts stock outlook - Investing.com
Taysha Gene Therapies price target raised to $14 from $11 at Canaccord - MSN
Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA) - The Globe and Mail
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $8 to $14 - 富途牛牛
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2025 Earnings Call Transcript - Insider Monkey
Canaccord Genuity raises Taysha Gene Therapies stock price target on pivotal study progress By Investing.com - Investing.com South Africa
Canaccord Genuity raises Taysha Gene Therapies stock price target on pivotal study progress - Investing.com Canada
Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028 - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates - MSN
Taysha Gene 2025 Q2 Earnings Significant Revenue Growth Despite Worsening Net Loss - AInvest
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... - Yahoo Finance
Taysha Gene Therapies Advances Rett Syndrome Trials - TipRanks
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - 富途牛牛
Chardan Capital Keeps Buy Rating on Taysha Gene with PT Raised to $10 - AInvest
Taysha Gene Therapies shares rise 6.70% intraday after reporting Q2 2025 earnings. - AInvest
Transcript : Taysha Gene Therapies, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Taysha Gene Therapies' Q2 2025: Key Contradictions in Clinical Trial Endpoints and Regulatory Strategy - AInvest
Taysha Gene Therapies, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Taysha Gene’s Q2 2025 revenue beats forecast By Investing.com - Investing.com UK
Earnings call transcript: Taysha Gene’s Q2 2025 revenue beats forecast - Investing.com
TSHATaysha Gene Therapies, Inc. Latest Stock News & Market Updates - Stock Titan
Is Taysha Gene Therapies Inc. benefiting from interest rate changesSteady Performer Watchlist - mustnews.co.kr
How does Taysha Gene Therapies Inc. perform in inflationary periodsBest Picks for Wealth Multiplication - newsyoung.net
Taysha Gene Therapies Inc. Reaches Critical Trendline SupportAlpha Focused Technical Trade Signals Gain Attention - beatles.ru
Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds - insights.citeline.com
Taysha Gene TSHA Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships and Innovation - AInvest
Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA) - MSN
Taysha Gene Therapies Inc. Breaks Losing Streak — Is the Trend ReversingPortfolio Diversification Stock Ideas From Experts - beatles.ru
Taysha Gene Therapies Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Earnings Preview: TSHA to Report Financial Results Pre-market on August 12 - 富途牛牛
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 - 富途牛牛
Taysha Gene Therapies to Release Second Quarter 2025 - GlobeNewswire
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know - Yahoo Finance
RSI Crosses Above 30 for Taysha Gene Therapies Inc. — Reversal in SightCommunity Shared Smart Money Signals Show Movement - beatles.ru
What are analysts’ price targets for Taysha Gene Therapies Inc. in the next 12 monthsDiscover undervalued stocks before they soar - Jammu Links News
What are Taysha Gene Therapies Inc. company’s key revenue driversBuild wealth with steady, reliable stocks - Jammu Links News
How many analysts rate Taysha Gene Therapies Inc. as a “Buy”Maximize gains with data-driven stock picks - Jammu Links News
What analysts say about Taysha Gene Therapies Inc. stockSuperior trading gains - Jammu Links News
10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey
What is Taysha Gene Therapies Inc. company’s growth strategyTriple returns potential - Jammu Links News
Is Taysha Gene Therapies Inc. stock overvalued or undervaluedUnlock real-time stock alerts for quick profits - Jammu Links News
How does Taysha Gene Therapies Inc. generate profit in a changing economyFree Trend-Following Techniques - Jammu Links News
What are the latest earnings results for Taysha Gene Therapies Inc.Maximize returns with strategic trading plans - Jammu Links News
What are the technical indicators suggesting about Taysha Gene Therapies Inc.Achieve triple-digit returns with smart investing - Jammu Links News
What makes Taysha Gene Therapies Inc. stock price move sharplyAchieve breakthrough financial growth - jammulinksnews.com
Taysha Gene Therapies Announces New Employee Stock Option Grant Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):